Additive Effects of MicroRNAs and Transcription Factors on CCL2 Production in Human White Adipose Tissue

  1. Peter Arner1
  1. 1Department of Medicine, Huddinge, Lipid Laboratory, Karolinska Institutet, Stockholm, Sweden
  2. 2RIKEN Center for Life Science Technologies, Division of Genomic Technologies, Yokohama, Japan
  3. 3Department of Biosciences and Nutrition, Huddinge, Karolinska Institutet, Stockholm, Sweden
  4. 4Akademikliniken, Stockholm, Sweden
  1. Corresponding authors: Peter Arner, peter.arner{at}ki.se, and Agné Kulyté, agne.kulyte{at}ki.se.

Abstract

Adipose tissue inflammation is present in insulin-resistant conditions. We recently proposed a network of microRNAs (miRNAs) and transcription factors (TFs) regulating the production of the proinflammatory chemokine (C-C motif) ligand-2 (CCL2) in adipose tissue. We presently extended and further validated this network and investigated if the circuits controlling CCL2 can interact in human adipocytes and macrophages. The updated subnetwork predicted that miR-126/-193b/-92a control CCL2 production by several TFs, including v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (ETS1), MYC-associated factor X (MAX), and specificity protein 12 (SP1). This was confirmed in human adipocytes by the observation that gene silencing of ETS1, MAX, or SP1 attenuated CCL2 production. Combined gene silencing of ETS1 and MAX resulted in an additive reduction in CCL2 production. Moreover, overexpression of miR-126/-193b/-92a in different pairwise combinations reduced CCL2 secretion more efficiently than either miRNA alone. However, although effects on CCL2 secretion by co-overexpression of miR-92a/-193b and miR-92a/-126 were additive in adipocytes, the combination of miR-126/-193b was primarily additive in macrophages. Signals for miR-92a and -193b converged on the nuclear factor-κB pathway. In conclusion, TF and miRNA-mediated regulation of CCL2 production is additive and partly relayed by cell-specific networks in human adipose tissue that may be important for the development of insulin resistance/type 2 diabetes.

Footnotes

  • Received May 3, 2013.
  • Accepted December 15, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

| Table of Contents

This Article

  1. Diabetes vol. 63 no. 4 1248-1258
  1. Supplementary Data
  2. All Versions of this Article:
    1. db13-0702v1
    2. 63/4/1248 most recent